Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Craniopharyngioma 2COVID-19 2Burkitt Lymphoma 2Arthritis, Rheumatoid 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Respiratory Tract Infections 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Etoposide 7pegaspargase 5Methylprednisolone 4Dexamethasone 4Cyclophosphamide 3Alemtuzumab 3Gemcitabine 2Doxorubicin 2zanubrutinib 1tocilizumab 1sintilimab 1ruxolitinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Th1-Th2 Balance 1Tacrolimus 1Rituximab 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylprednisolone Hemisuccinate 1Methotrexate 1Melphalan 1Flow Cytometry 1EPOCH protocol 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphohistiocytosis, Hemophagocytic × tocilizumab × Clear all
NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 10 charts
MyeloidOther hematologic neoplasm

Leukemia, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡